The largest database of trusted experimental protocols

Sta liquid fib

Manufactured by Diagnostica Stago
Sourced in France

The STA Liquid Fib is a laboratory instrument designed for the quantitative determination of fibrinogen concentration in human plasma samples. It utilizes a coagulometric method to measure the time required for fibrin clot formation after the addition of a reagent.

Automatically generated - may contain errors

6 protocols using sta liquid fib

1

Coagulation Assessment via Stago and ROTEM

Check if the same lab product or an alternative is used in the 5 most similar protocols
Stago Analysis: Prothrombin time (PT, sec), activated partial thromboplastin time (aPTT, sec), and fibrinogen (g/dL) were measured on the STA Compact (Diagnostica Stago, Doncaster, Australia) using reagents STA Neoplastine Cl (rabbit brain), Triniclot aPTT HS, and STA Liquid Fib. Rotational Thromboelastometry (ROTEM®): ROTEM® (Tem International, Munich, Germany) was conducted according to manufacturer’s instructions with all kinetic, elongation and lysis parameters defined in Letson and Dobson [22 , 26 (link)]. Quality control measurements (ROTROL-N and ROTROL-P) were performed weekly.
+ Open protocol
+ Expand
2

Hemostasis Evaluation: Coagulation Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols
Prothrombin time (PT) (Neoplastin, Diagnostica Stago, Asnières sur Seine, France) and activated partial thromboplastin time (aPTT) (PTT-A, Diagnostic Stago, Asnières sur Seine, France) were measured with STAR Max. Fibrinogen levels were measured in plasma by Clauss clotting method (STA-Liquid Fib, Diagnostica Stago, Asnières, France). All hemostasis tests were performed in citrated plasma samples.
+ Open protocol
+ Expand
3

Quantitative Analysis of Fibrinolytic Biomarkers

Check if the same lab product or an alternative is used in the 5 most similar protocols
The plasma concentration of fibrinogen and D-Dimer was quantitatively determined using the STA-Liquid fib and the Liatest D-Di kits (Diagnostica Stago, Asnieres-sur-Seine, Paris, France), respectively, and a STA-R coagulation analyser (Diagnostica Stago). In-house prepared ELISAs employing specific mAbs were used to determine the plasma concentration of tPA and PAI-1 [31 (link)].
The rate of fibrin formation (Vmax) and fibrin structure measurements (mass-length ratio [(ML), diameter (Diam) and density (Dens)] and fibrin clot lysis were determined according to Sjøland et al.[32 (link)] using turbidity measurements
Fibrin clot lysis was measured by mixing 60 μl of plasma with 120 μl of a reaction mixture consisting of 1 IU/ml of thrombin, 15 mmol/l CaCl2, 50 mmol/l Tris-HCL buffer, 150 mmol/l NaCl and 0.6 mg/ml recombinant tPA (Boehringer Ingelheim, Ingelheim am Rhein, Germany). The optical density at 340 nm (OD340) was recorded for 30 min, and the percentage of the clot lysed thereafter was determined. Measures of fibrin clot properties was determined using a similar setup, but replacing rtPA with Tris-HCl buffer. The fibrin fibre properties (i.e. Vmax, mass-length, Diam and Dens) were determined by measurements of OD405, OD560, OD608 and OD690 of the fibrin clot and calculated according to Carr et al.[33 (link),34 (link)].
+ Open protocol
+ Expand
4

Comprehensive Coagulation Biomarker Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols
Blood was collected at ICU admission for each patient on 0.109 mol/L trisodium citrate tube (BD Vacutainer, BD Diagnostics, Sparks, MD, USA). All analyses were performed on platelet-poor plasma obtained after a double centrifugation at 2500× g for 15 min at room temperature.
The following biomarkers were measured in the derivation and validation cohorts: Prothrombin time and fibrinogen were measured on an STA-R Max analyzer (Diagnostica Stago, Asnières-sur-Seine, France) using STA® Neoplastin® R (Diagnostica Stago) and STA®Liquid-Fib (Diagnostica Stago); D-dimers levels were measured in µg/mL (fibrinogen equivalent units) using an immunoturbidimetric latex-particle assay (Liatest® DDI-Plus, Diagnostica Stago) on the STA-R Max analyzer (Diagnostica Stago); and Von Willebrand factor antigen (VWF:Ag) was measured using an immunoturbidimetric assay (LIAPHEN® VWF:Ag, HYPHEN BioMed, Andresy, France) on a CS 2400 analyzer (Sysmex, Kobe, Japan). Endocan was measured using the JDIYEK® ELISA Kit (Biothelis, Lille, France). Other laboratory blood tests including a complete blood count, CRP, procalcitonin (PCT), liver transaminases, bilirubin, and creatinine were measured by standard methods as part of the patient’s care in the Biology and Pathology Center of Lille University Hospital.
+ Open protocol
+ Expand
5

Comprehensive Hemostasis Evaluation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Haemostasis tests included the measure of the activated partial thromboplastin time (aPTT; STA-PTT A, Diagnostica Stago, Asnières-sur-Seine, France), prothrombin time (PT; STA-NeoPTimal 10, Diagnostica Stago, Asnières-sur-Seine, France), fibrinogen (functional clotting assay according to Clauss; STA-Liquid Fib, Diagnostica Stago, Asnières-sur-Seine, France), antithrombin (colorimetric assay; STA-Stachrom AT III, Diagnostica Stago, Asnières-sur-Seine, France), and D-dimer (immunoturbidimetric assay; STA-Liatest D-DI PLUS, Diagnostica Stago, Asnières-sur-Seine, France). All tests were performed on the automated coagulometer (STA-R Evolution, Diagnostica Stago, Asnières-sur-Seine, France).
+ Open protocol
+ Expand
6

Fibrinogen Maintenance in Trauma

Check if the same lab product or an alternative is used in the 5 most similar protocols
The primary endpoint was the fibrinogen concentration (STA Liquid Fib, Diagnostica Stago, Asnières sur Seine, France) at 45 min after randomization. Secondary endpoints included: (i) the rate of patients with a fibrinogen concentration above the recommended 1.5 g L -1 threshold at 45 min, (ii) changes from randomization in hemostatic parameters measured at different time-points (45 min, 6, 12 and 24 h after randomization), including fibrinogen concentration, prothrombin time (PT) ratio (STA Neoplastin R15, Diagnostica Stago), activated partial thromboplastin time (APTT) ratio (Triniclot aptt HS, Diagnostica Stago), coagulation factors II and V (Plasma deficient FII, FV, Diagnostica Stago), fibrin monomer (Liatest FM, Diagnostica Stago), base excess and serum lactate (ABL800 FLEX, Radiometer, Copenhagen,Denmark); (iii) time to transfusion, including interval between randomization and transfusion of the first plasma unit and interval between randomization to end of transfusion of the fourth plasma unit, (iv) fibrinogen concentrate and blood product requirements over the first 24 h after randomization, and (v) all-cause hospital death within 30 days of injury.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!